Trial Details
COMPLETEDBasic Information
| Clinical ID | c1069 |
|---|---|
| Identifier | NCT02039505 |
| Trial Title | Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Ulcerative Colitis |
| Interventions | DRUG: Vedolizumab|DRUG: Vedolizumab placebo |
Participant Information
| Sponsor | Takeda |
|---|---|
| City | Kasugai-shi |
| Country/Region | Japan |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | CHILD, ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2014-02-04 |
|---|---|
| Primary Completion Date | 2018-02-27 |
| Completion Date | 2018-06-28 |